Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) announces the following updates in connection with the Company’s previously announced merger with Treeline Biosciences, Inc. (“Treeline”): Agreement to sell its Mass Cytometry business to Multiplex Bio, an entity founded and led by advanced imaging industry veterans, Michael Johnson, PhD, Tom Villani, PhD and Charles Coffman; Buyout of the 2026 earnout and all future royalty payments for $30 million related to Illumina, Inc.’s previously completed acquisition of Standard BioTools’ SomaLogic business; and Early termination of the waiting period by the U.S. Federal Trade Commission under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to the Treeline merger.
Read the full article: Standard BioTools Announces Sale of Mass Cytometry Business and Illumina’s Buyout of Contingent Payments to Advance Merger with Treeline Biosciences //
Source: https://www.globenewswire.com/news-release/2026/07/28/3334170/0/en/standard-biotools-announces-sale-of-mass-cytometry-business-and-illumina-s-buyout-of-contingent-payments-to-advance-merger-with-treeline-biosciences.html